Table 3.
Outcome in 103 Takotsubo syndrome (TTS) patients and 422 acute coronary syndrome (ACS) patients both treated with ß-antagonists.
| Variables |
TTS (n=103) |
ACS (n=422) |
Relative risk (95% CI) | p value* |
|---|---|---|---|---|
| In-hospital mortality | 0 (0.0) | 1 (0.2) | 0.62 | |
| 30-day mortality | 1 (1.0) | 2 (0.5) | 2.0 (0.2-22.4) | 0.55 |
| Long-term mortality | 18 (17.5) | 15 (3.6) | 4.9 (2.6-9.4) | <0.01 |
| Cardiovascular cause of death | 5 (4.9) | 14 (3.3) | 1.5 (0.5-4.0) | 0.45 |
| Non-cardiovascular cause of death | 6 (5.8) | 1 (0.2) | 8.2 (2.1-32.2) | <0.01 |
| Unknown cause of death | 7 (6.8) | 0 (0.0) | <0.01 | |
| 30-day Stroke | 4 (3.9) | 4 (0.9) | 4.1 (1.0-16.1) | 0.03 |
| Long-term Stroke | 6 (5.8) | 16 (3.8) | 1.5 (0.6-3.8) | 0.36 |
| 30-day life-threatening arrythmia | 7 (6.8) | 28 (6.6) | 1.2 (0.6-2.5) | 0.68 |
| Long-term life-threatening arrythmia | 8 (7.8) | 32 (7.6) | 1.2 (0.6-2.3) | 0.69 |
| 30-day Heart Failure | 2 (1.9) | 20 (4.7) | 0.4 (0.1-1.7) | 0.20 |
| Long-term Heart Failure | 3 (2.9) | 55 (13.0) | 0.2 (0.1-0.7) | <0.01 |
| 30-day Recurrence | 0 (0.0) | 6 (1.4) | 0.22 | |
| Long-term Recurrence | 6 (5.8) | 46 (10.9) | 0.5 (0.2-1.2) | 0.12 |
| 30-day Thromboembolic Events | 15 (14.6) | 11 (2.6) | 5.6 (2.6-11.8) | <0.01 |
| Long-term Thromboembolic Events | 19 (18.4) | 30 (7.1) | 2.6 (1.5-4.4) | <0.01 |
*p values for the comparison between TTS and ACS patients.